Allergen specific immunotherapy: New approaches;Allergenspezifische immuntherapie: Auf neuen wegen in die zukunft

Praxis

Volumn 99, Issue 21, 2010, Pages 1279-1284

  Tay, Fabian ^a   Kundig T M ^b   Senti, G ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Desensitization; Epicutaneous; Patch; Specific immunotherapy; Transcutaneous

Indexed keywords

ALLERGEN; IMMUNOGLOBULIN E;

ALLERGEN SPECIFIC IMMUNOTHERAPY; ALLERGIC DISEASE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GOLD STANDARD; HUMAN; IMMUNOTHERAPY; SHORT SURVEY; SUBCUTANEOUS IMMUNOTHERAPY; TRANSDERMAL PATCH;

EID: 78049362032     PISSN: 16618157     EISSN: 16618165     Source Type: Journal    
DOI: 10.1024/1661-8157/a000276     Document Type: Short Survey

References (21)

1. Arbes SJ, Jr., Gergen PJ, Elliott L, Zeldin DC. Prevalences of positive skin test responses to 10 common allergens in the US population: results from the third National Health and Nutrition Examination Survey. J Allergy Clin Immunol 2005;116:377-383. (Pubitemid 41096546)
2. Wuthrich B, Schindler C, Leuenberger P, Ackermann-Liebrich U. Prevalence of atopy and pollinosis in the adult population of Switzerland (SAPALDIA study). Swiss Study on Air Pollution and Lung Diseases in Adults. Int Arch Allergy Immunol 1995;106:149-156.
3. Durham SR, Walker SM, Varga EM, et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 1999;341:468-475. (Pubitemid 29372886)
4. Pajno GB, Barberio G, De Luca F, Morabito L, Parmiani S. Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study. Clin Exp Allergy 2001;31:1392-1397. (Pubitemid 32823876)
5. Freeman J. Further observations on the treatment of hay fever by hypodermic inoculations of pollen vaccine. Historical document. Ann Allergy 1960;18:427-434.
6. Dolz I, Martinez-Cocera C, Bartolome JM, Cimarra M. A double-blind, placebo-controlled study of immunotherapy with grass-pollen extract Alutard SQ during a 3-year period with initial rush immunotherapy. Allergy 1996;51:489-500. (Pubitemid 26254936)
7. Varney VA, Hamid QA, Gaga M, et al. Influence of grass pollen immunotherapy on cellular infiltration and cytokine mRNA expression during allergen-induced late-phase cutaneous responses. J Clin Invest 1993;92:644-651. (Pubitemid 23262381)
8. Pierson-Mullany LK, Jackola D, Blumenthal M, Rosenberg A. Altered allergen binding capacities of Amb a 1-specific IgE and IgG4 from ragweed-sensitive patients receiving immunotherapy. Ann Allergy Asthma Immunol 2000;84:241-243. (Pubitemid 30141606)
9. Larche M, Akdis CA, Valenta R. Immunological mechanisms of allergen-specific immunotherapy. Nat Rev Immunol 2006;6:761-771. (Pubitemid 44453462)
10. Calderon MA, Alves B, Jacobson M, Hurwitz B, Sheikh A, Durham S. Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev 2007:CD001936.
11. J. Kleine-Tebbe AB, C. Ebner, P. Eigenmann, F. Friedrichs, Th. Fuchs, I. Huttegger, K. Jung, L. Klimek, M. Kopp, W. Lässig, H. Merk, B. Niggemann, U. Rabe, J. Saloga, P. Schmid-Grendelmeier, H. Sitter, J. C. Virchow, M. Wagenmann, B. Wedi, M. Worm. Specific immunotherapy (hyposensitization) for IgE-mediated allergic diseases Allergo J 2009: 18: 508-537
12. Warner JO. A century of immunotherapy. Pediatr Allergy Immunol 2008;19:569-570.
13. Bousquet J, Van Cauwenberge P, Khaltaev N. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001;108:S147-334.
14. Calderon MA, Birk AO, Andersen JS, Durham SR. Prolonged preseasonal treatment phase with Grazax sublingual immunotherapy increases clinical efficacy. Allergy 2007;62:958-961. (Pubitemid 47037855)
15. Jutel M, Jaeger L, Suck R, Meyer H, Fiebig H, Cromwell O. Allergen-specific immunotherapy with recombinant grass pollen allergens. J Allergy Clin Immunol 2005;116:608-613. (Pubitemid 41267135)
16. Senti G, Johansen P, Kundig TM. Intralymphatic immunotherapy. Curr Opin Allergy Clin Immunol 2009;9:537-543.
17. Senti G, Prinz Vavricka BM, Erdmann I, et al. Intralymphatic allergen administration renders specific immunotherapy faster and safer: a randomized controlled trial. Proc Natl Acad Sci USA 2008;105:17908-17912.
18. Senti G, Johansen P, Haug S, et al. Use of A-type CpG oligodeoxynucleotides as an adjuvant in allergen-specific immunotherapy in humans: a phase I/IIa clinical trial. Clin Exp Allergy 2009;39:562-570.
19. Senti G, Graf N, Haug S, et al. Epicutaneous allergen administration as a novel method of allergen-specific immunotherapy. J Allergy Clin Immunol 2009;124:997-1002.
20. Frech SA, Dupont HL, Bourgeois AL, et al. Use of a patch containing heat-labile toxin from Escherichia coli against travellers' diarrhoea: a phase II, randomised, double-blind, placebo-controlled field trial. Lancet 2008;371:2019-2025.
21. Glenn GM, Taylor DN, Li X, Frankel S, Montemarano A, Alving CR. Transcutaneous immunization: a human vaccine delivery strategy using a patch. Nat Med 2000;6:1403-1406. (Pubitemid 32001027)